Literature DB >> 15291347

Low dose total body irradiation followed by allogeneic lymphocyte infusion for refractory hematologic malignancy--an updated review.

Karen K Ballen1, Gerald Colvin, David Porter, Peter J Quesenberry.   

Abstract

Allogeneic stem cell transplantation is curative for certain cancers, but the high doses of chemotherapy and radiotherapy used in conventional myeloablative conditioning regimens may lead to severe toxicity. In our initial study, we treated 25 patients with refractory cancers with 100 cGy total body irradiation (TBI) followed by allogeneic, non mobilized peripheral blood cells. Eighteen patients received sibling and 7 patients received unrelated cord blood stem cells. None of the 13 patients with solid tumors achieved donor chimerism or had a sustained response. Twelve patients with hematologic malignancies were treated, 1 received a cord blood transplant and 11 received sibling donor cells. Nine of these 11 patients achieved donor chimerism, ranging from 5% to 100%. Four patients had sustained complete remission of their cancers, and 2 are long-term survivors. The development of chimerism correlated with total previous myelotoxic chemotherapy (p < 0.001). This technique is now being extended into the haploidentical setting.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15291347      PMCID: PMC1986764          DOI: 10.1080/10428190310001628167

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  36 in total

1.  Donor leukocyte infusions in acute myelogenous leukemia.

Authors:  D L Porter
Journal:  Leukemia       Date:  2003-06       Impact factor: 11.528

Review 2.  Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood?

Authors:  Satkiran S Grewal; Juliet N Barker; Stella M Davies; John E Wagner
Journal:  Blood       Date:  2003-01-09       Impact factor: 22.113

3.  Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.

Authors:  I F Khouri; R M Saliba; S A Giralt; M S Lee; G J Okoroji; F B Hagemeister; M Korbling; A Younes; C Ippoliti; J L Gajewski; P McLaughlin; P Anderlini; M L Donato; F F Cabanillas; R E Champlin
Journal:  Blood       Date:  2001-12-15       Impact factor: 22.113

4.  Racial and ethnic composition of volunteer cord blood donors: comparison with volunteer unrelated marrow donors.

Authors:  Karen K Ballen; Julie Hicks; Bernie Dharan; Daniel Ambruso; Kenneth Anderson; Celso Bianco; Lynn Bemiller; William Dickey; Richard Lottenberg; Mary O'Neill; Mark Popovsky; Donna Skerrett; Irena Sniecinski; John R Wingard
Journal:  Transfusion       Date:  2002-10       Impact factor: 3.157

5.  Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer.

Authors:  Marco Bregni; Anna Dodero; Jacopo Peccatori; Alessandra Pescarollo; Massimo Bernardi; Isabella Sassi; Claudia Voena; Alberto Zaniboni; Claudio Bordignon; Paolo Corradini
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

6.  Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.

Authors:  B R Dey; S McAfee; R Sackstein; C Colby; S Saidman; D Weymouth; C Poliquin; J Vanderklish; D H Sachs; M Sykes; T R Spitzer
Journal:  Biol Blood Marrow Transplant       Date:  2001       Impact factor: 5.742

7.  Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy.

Authors:  Karen K Ballen; Pamela S Becker; Robert V B Emmons; Thomas J Fitzgerald; Chung C Hsieh; Qin Liu; Christine Heyes; Yeteive Clark; William Levy; Jean Francois Lambert; Frank Chiafari; Irma Szymanski; Sarah Rososhansky; Mark A Popovsky; F Marc Stewart; Peter J Quesenberry
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

8.  Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation.

Authors:  Bimalangshu R Dey; Steven McAfee; Christine Colby; Robert Sackstein; Susan Saidman; Nancy Tarbell; David H Sachs; Megan Sykes; Thomas R Spitzer
Journal:  Biol Blood Marrow Transplant       Date:  2003-05       Impact factor: 5.742

9.  H2-mismatched transplantation with repetitive cell infusions and CD40 ligand antibody infusions without myeloablation.

Authors:  Jean-François Lambert; Gerald A Colvin; Suju Zhong; Han Wang; Lionel D'Hondt; Mehrdad Abedi; Angela E Frimberger; F Marc Stewart; Peter J Quesenberry
Journal:  Br J Haematol       Date:  2002-10       Impact factor: 6.998

10.  Nonmyeloablative bone marrow transplantation: Infectious complications in 65 recipients of HLA-identical and mismatched transplants.

Authors:  Andrew Daly; Steven McAfee; Bimal Dey; Christine Colby; Leah Schulte; Beow Yeap; Robert Sackstein; Nancy J Tarbell; David Sachs; Megan Sykes; Thomas R Spitzer
Journal:  Biol Blood Marrow Transplant       Date:  2003-06       Impact factor: 5.742

View more
  3 in total

1.  Defining the intensity of conditioning regimens: working definitions.

Authors:  Andrea Bacigalupo; Karen Ballen; Doug Rizzo; Sergio Giralt; Hillard Lazarus; Vincent Ho; Jane Apperley; Shimon Slavin; Marcelo Pasquini; Brenda M Sandmaier; John Barrett; Didier Blaise; Robert Lowski; Mary Horowitz
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-01       Impact factor: 5.742

2.  Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis.

Authors:  Gabriela Rondón; Rima M Saliba; Issa Khouri; Sergio Giralt; Kawah Chan; Elias Jabbour; John McMannis; Richard Champlin; Elizabeth Shpall
Journal:  Biol Blood Marrow Transplant       Date:  2008-08       Impact factor: 5.742

3.  Total Body Irradiation for Hematopoietic Stem Cell Transplantation: What Can We Agree on?

Authors:  Mitchell Sabloff; Steven Tisseverasinghe; Mustafa Ege Babadagli; Rajiv Samant
Journal:  Curr Oncol       Date:  2021-02-14       Impact factor: 3.677

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.